ArticleProceedings of the National Academy of Sciences of the United States of America2011
Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Prevalence and risk of Plasmodium vivax infection among Duffy-negative individuals: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Association between ABO and Duffy blood types and circulating chemokines and cytokines.Genes and immunity · 2021Trial
- Trial
- Identification and Characterization of Functional Human Monoclonal Antibodies toJournal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Epidemiological insights and genetic diversity of the Duffy binding protein of Plasmodium vivax in Duffy-negative Cameroonians.PLoS neglected tropical diseases · 2026Article
- Genetic variation in the Duffy blood group among vivax malaria patients and its impact on disease susceptibility.Malaria journal · 2026Article
- How Duffy Blood Group (FY) Polymorphism and Age Modulate Vivax Malaria Risk at the Community Level: A Population-based Retrospective Cohort Study in the Amazon.The Journal of infectious diseases · 2026Article
- Invasion preferences suggest a possible role for Plasmodium falciparum parasites in the expansion of Duffy negativity in West and Central Africa.Molecular biology and evolution · 2026Article
- Complete gene sequence diversity, amplification, and natural selection of the Plasmodium vivax Duffy binding protein locus.Malaria journal · 2025Article
- The pattern of gene amplification of members of the Plasmodium vivax erythrocyte binding-like proteins family across the Amazon rainforest.Malaria journal · 2025Article
- Encoding and decoding selectivity and promiscuity in the human chemokine-GPCR interaction network.Cell · 2025Article
- Emerging concepts in the molecular cell biology and functions of mammalian erythrocytes.The Journal of biological chemistry · 2025Review
- Spatial distribution of Plasmodium vivax Duffy Binding Protein copy number variation and Duffy genotype, and their association with parasitemia in Ethiopia.PLoS neglected tropical diseases · 2025Article
- Blood group antigens and malaria susceptibility.Frontiers in cellular and infection microbiology · 2025Review
- Duffy Antigen Receptor for Chemokines (DARC) Polymorphisms and Susceptibility to Plasmodium Vivax Malaria in Sudan: a Case - Control Study.Materia socio-medica · 2025Article
- Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and health centre collections in Ethiopia.Malaria journal · 2024Article
- Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions.Cell genomics · 2024Article
- Duffy antigen is expressed during erythropoiesis in Duffy-negative individuals.Cell host & microbe · 2023Article
- Infectious diseases may have arrested the southward advance of microblades in Upper Palaeolithic East Asia.Proceedings. Biological sciences · 2023Article
- Vaccination withScience translational medicine · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
Abstract
Plasmodium vivax (Pv) is a major cause of human malaria and is increasing in public health importance compared with falciparum malaria. Pv is unique among human malarias in that invasion of erythrocytes is almost solely dependent on the red cell's surface receptor, known as the Duffy blood-group antigen (Fy). Fy is an important minor blood-group antigen that has two immunologically distinct alleles, referred to as Fy(a) or Fy(b), resulting from a single-point mutation. This mutation occurs within the binding domain of the parasite's red cell invasion ligand. Whether this polymorphism affects susceptibility to clinical vivax malaria is unknown. Here we show that Fy(a), compared with Fy(b), significantly diminishes binding of Pv Duffy binding protein (PvDBP) at the erythrocyte surface, and is associated with a reduced risk of clinical Pv in humans. Erythrocytes expressing Fy(a) had 41-50% lower binding compared with Fy(b) cells and showed an increased ability of naturally occurring or artificially induced antibodies to block binding of PvDBP to their surface. Individuals with the Fy(a+b-) phenotype demonstrated a 30-80% reduced risk of clinical vivax, but not falciparum malaria in a prospective cohort study in the Brazilian Amazon. The Fy(a+b-) phenotype, predominant in Southeast Asian and many American populations, would confer a selective advantage against vivax malaria. Our results also suggest that efficacy of a PvDBP-based vaccine may differ among populations with different Fy phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.